Endoscopic Full Thickness Biopsy, Gastric Wall.

Sponsor
Mayo Clinic (Other)
Overall Status
Completed
CT.gov ID
NCT01650714
Collaborator
(none)
3
1
1
24
0.1

Study Details

Study Description

Brief Summary

The proposed study will assess the efficacy and safety of the innovative endoscopic technique for the acquisition of full thickness gastric muscle wall biopsies. Having access to full thickness biopsies will allow an increased understanding of the pathophysiology of gastrointestinal diseases such as functional gastrointestinal disorders, gastroparesis, pseudoobstruction and other motility disorders. This information is essential to development of more targeted and effective therapy than currently available. Despite the high prevalence of functional gastrointestinal disorders and its significant impact on social and health care costs, the underlying cause is not well understood and there is no effective specific treatment to successfully alleviate patient symptoms.

Condition or Disease Intervention/Treatment Phase
  • Other: Full thickness gastric biopsy
  • Procedure: Full thickness gastric biopsy
N/A

Detailed Description

Our group has studied a new endoscopic method using a submucosal endoscopy with mucosal flap (SEMF) technique to acquire full thickness gastric tissues successfully and safely in preclinical studies.

The proposed study will assess the efficacy and safety of the innovative endoscopic technique for the acquisition of full thickness gastric muscle wall biopsies. Having access to full thickness biopsies will allow an increased understanding of the pathophysiology of gastrointestinal diseases such as functional gastrointestinal disorders, gastroparesis, pseudoobstruction and other motility disorders. This information is essential to development of more targeted and effective therapy than currently available. Despite the high prevalence of functional gastrointestinal disorders and its significant impact on social and health care costs, the underlying cause is not well understood and there is no effective specific treatment to successfully alleviate patient symptoms.

Study Design

Study Type:
Interventional
Actual Enrollment :
3 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Endoscopic Full Thickness Biopsy of the Gastric Wall in Patients With Refractory Idiopathic Gastroparesis: Pilot Study to Detect Neuromuscular and Immune Pathologic Changes
Study Start Date :
Sep 1, 2012
Actual Primary Completion Date :
Sep 1, 2014
Actual Study Completion Date :
Sep 1, 2014

Arms and Interventions

Arm Intervention/Treatment
Experimental: Full thickness gastric biopsy

Full thickness gastric biopsy

Other: Full thickness gastric biopsy

Procedure: Full thickness gastric biopsy

Outcome Measures

Primary Outcome Measures

  1. Number of patients with successful endoscopic full thickness gastric resection [one week after surgery]

    Success of the endoscopic resection will be defined by efficacy and safety: 1) Efficacy is defined as obtaining a full thickness resection and 2) Safety is defined as the absence of serious adverse events.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 70 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Symptomatic refractory idiopathic gastroparesis:

  2. The refractory nature of symptoms (e.g. based on nutritional failure, consideration for enteral or parenteral nutrition) will be determined by the physician/gastroenterologist who is the primary care provider for the patient's gastroparesis.

  3. Patients will have documentation within the last 2 years of delayed gastric emptying with >30% retained gastric contents at 4 hours based on 296 kcal solid-liquid, fat-containing standard meal gastric emptying test.

  4. The patient's physician will determine if this procedure may potentially provide prognostic and therapeutic options.

  5. Age > 18 and < 70 years old

  6. Hemoglobin (Hb) > 10g, platelets >150,000 and prothrombin time- international normalized ratio (INR) <1.5

  7. Ability to give informed consent

Exclusion Criteria:
  1. Prior oropharyngeal, esophageal, gastric or small bowel surgery

  2. Esophageal stricture

  3. Prior abdominal radiation therapy

  4. Prior feeding tube placement

  5. Coagulopathy

  6. Use of Coumadin or anti-platelet drugs e.g. Plavix, steroids or immunosuppressive drugs

  7. Pregnancy -

Contacts and Locations

Locations

Site City State Country Postal Code
1 Mayo Clinic Rochester Minnesota United States 55902

Sponsors and Collaborators

  • Mayo Clinic

Investigators

  • Principal Investigator: Elizabeth Rajan, MD, Mayo Clinic

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Elizabeth Rajan, MD, Mayo Clinic
ClinicalTrials.gov Identifier:
NCT01650714
Other Study ID Numbers:
  • 12-000714
First Posted:
Jul 26, 2012
Last Update Posted:
May 14, 2015
Last Verified:
May 1, 2015
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 14, 2015